Why are you so angry and how am I spreading FUD?
Post# of 148154
The DSMC @ 50% review made a recommendation to look at 42 days. Why do they make a recommendation? To hurt the trial outcome? No, to help the trial outcome. So, they saw that there were deaths not being counted that COULD help leronlimab show a mortality benefit (now we know there were 8 deaths outside 28 days). Per the PR, I notice the PE for mITT (384 patients) when adjusted for age was very close to stat sig. Again, using logical deduction, knowing the DSMC recommendation is intended to help the outcome, I opine that being able to include those 8 deaths, COULD possibly have helped achieve stat significance. Agree that CD12 was hampered in part by bad luck and part bad design (or bad recruitment) so we needed all the help we can get.
Again, not understanding why I'm being accused of spreading FUD and why you are so angry.